| name | endo-discontinue-pegvisomant-if-lftgt3x |
| description | Consider discontinuing pegvisomant when alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeds three times the upper limit of normal (ULN) during routine monthly liver function testing. This trigger applies to patients receiving pegvisomant for acromegaly who demonstrate transaminase elevations >3× ULN on LFT monitoring. |
Consider discontinuing pegvisomant if transaminases exceed three-fold upper limit of normal
STEP 1 — Gather Information
Collect current ALT/AST values, baseline LFT, pegvisomant dose and duration, presence of symptoms (fatigue, jaundice, abdominal pain), concomitant hepatotoxic medications, alcohol use, and comorbidities.
Action: Proceed to evaluate whether transaminases exceed 3× ULN.
STEP 2 — Rule In / Rule Out
Is ALT or AST >3× ULN?
- Yes: Rule in pegvisomant‑associated hepatotoxicity and proceed to Step 3.
- No: Rule out significant hepatotoxicity and continue pegvisomant with routine monthly LFT monitoring.
Decision: Based on the binary fork, either advance to classification or maintain current therapy.
STEP 3 — Classify or Stratify
Classify elevation as mild (3–5× ULN), moderate (5–10× ULN), or severe (>10× ULN) and assess for symptoms or signs of liver injury (jaundice, coagulopathy, encephalopathy).
Decision: If mild and asymptomatic, consider a temporary dose hold with repeat LFT in 1 week; if moderate/severe or symptomatic, prepare for discontinuation.
STEP 4 — Decide
If transaminases remain >3× ULN on repeat testing or are associated with clinical hepatitis, discontinue pegvisomant and initiate alternative medical therapy (e.g., somatostatin receptor ligand or cabergoline) to maintain IGF‑1 control; if elevation resolves with hold, consider rechallenge at a lower dose under close LFT surveillance.
Action: Implement the chosen therapeutic adjustment.
Clinical Guardrails / Mimics / Pitfalls
Do not attribute ALT/AST rise solely to pegvisomant without excluding other causes (viral hepatitis, alcohol, statins); do not discontinue based on a single abnormal LFT without confirmation; avoid stopping pegvisomant without arranging alternative disease‑controlling therapy; do not ignore concomitant use of other hepatotoxic agents.
Concrete Clinical Example
A 48‑year‑old man on pegvisomant 20 mg daily for 5 months presents with routine LFT showing ALT 210 U/L (ULN 40) = 5.25× ULN and AST 190 U/L (ULN 35) = 5.4× ULN, asymptomatic, no alcohol or new meds. Repeat LFT after 1 week shows ALT 205 U/L, AST 185 U/L.
Decision: Hold pegvisomant, start lanreotide autogel 90 mg monthly, and monitor LFT weekly; after normalization, consider pegvisomant reintroduction at 10 mg daily if needed.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700
